.png){kind=icon}
.png){kind=icon}
Return
Post-Marketing Safety Surveillance of Autoimmune Diseases Following Bivalent Human Papillomavirus Vaccination in China
.png){kind=icon}
OA
AI
X
X
Q
B
M
H
X
T
Y
S
H
L
DOI：10.3390/vaccines14080687.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Background/Objectives: The potential of vaccines to trigger autoimmune diseases (ADs) has been extensively investigated and remains a routine focus of vaccine-safety research. This post-marketing, real-world study compared the risk of ADs between females who received bivalent human papillomavirus (HPV) vaccine (Cecolin) and unvaccinated females. Methods: Eligible females aged 9–45 years registered in the Xiamen Health and Medical Big Data Center from September 2020 to December 2023 (post-Cecolin period) were enrolled. Cecolin recipients constituted the exposed cohort, and a matched unexposed cohort was generated in a 1:4 ratio based on age and calendar year. Case validation was conducted to determine optimal identification algorithms. Incidence rates (IRs) were calculated and incidence rate ratios (IRRs) with 95% confidence intervals (CIs) were derived from zero-inflated Poisson regression. Results: Overall incidence of ADs was 70.63 per 100,000 person-years (95% CI: 67.59–73.77) in the post-Cecolin period. Compared with matched unexposed cohorts, vaccinated females showed a significantly lower AD risk in both contemporaneously matched (IRR = 0.23, 95% CI: 0.08–0.65; p = 0.006) and historically matched (IRR = 0.21, 95% CI: 0.07–0.66; p = 0.008) analyses. Conclusions: Consistent with prior evidence, this study provides real-world evidence further confirming that Cecolin vaccination does not increase the risk of ADs. It adds the first large-scale post-marketing safety evidence for this Chinese domestic bivalent HPV vaccine, filling a critical evidence gap. These results may inform vaccination policy and guide post-licensure safety monitoring in China and other countries that have introduced this vaccine.
Keywords:
autoimmune diseases
human papillomavirus vaccine
post-marketing
real-world
safety
Journal
IF:
3.4
Papers:
1.0W
Citations:
2.6W
Organization
Cited Papers